However, some patients are at risk of developing MS after taking medication, and the current clinical mechanism for causing MS is still inconclusive, which may be related to the blockade effects of monoamine neurotransmitters such as histamine, norepinephrine, M receptors, and 5-HT.[33–35] After the monoamine neurotransmitter is blocked, the patient’s appetite is enhanced, and it also has a sedative effect, which can increase the patient’s food intake, reduce the amount of exercise, and increase the accumulated energy in the body. The gene discussed is HTR5A; the disease is myeloid sarcoma.